Latest Regulatory Risk News

Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.

Nexion Group has agreed to sell its telecommunications subsidiaries for $4.1 million, aiming to reduce debt and pivot towards its high-growth AI and business intelligence operations.

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

Qantas Airways posted a robust FY25 financial performance with a 28% rise in statutory profit after tax, supported by strong travel demand and strategic fleet investments. The Group also announced substantial dividends and completed a $431 million share buy-back, while closing Jetstar Asia to focus on core markets.

Medibank Private Limited reported steady revenue growth and stable profit for FY25, while navigating ongoing cybercrime-related expenses and regulatory scrutiny. The insurer also announced increased dividends and outlined strategic investments in health services and digital transformation.